Skip to main content
. 2017 Jun 7;9(2):21. doi: 10.3390/pharmaceutics9020021

Figure 12.

Figure 12

Proposed surface modification model for a drug-loaded CA particle. Surface modification involves PEGylation and attachment of a targeting moiety to drug–apatite complexes. Streptavidin was used as a linker between drug–apatite particles and biotin–PEG, since biotin has specific affinity towards straptavidin. A cell-targeting moiety, such as fibronectin, is attached to the particles via ionic interactions.